CEA-Scan arcitumomab nuclear imaging agent: Data from a physician-sponsored study; marketed to detect colorectal cancer

IMMU said data from a U.S. trial in 14 breast cancer

Read the full 111 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE